Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NovoCare Pharmacy vs Royal Medical Center

NovoCare Pharmacy
Graded #442

Higher grade

vs+5.800000000000004
Royal Medical Center
Graded #492

Lower grade

The verdict

NovoCare Pharmacy takes it — 55.2/100 to 49.4/100.

NovoCare Pharmacy grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Novo Nordisk's first-party direct-to-consumer pharmacy for branded Wegovy (semaglutide).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNovoCare Pharmacy +2
24
22
Dose & formulationNovoCare Pharmacy +24
66
42
Clinical oversightNovoCare Pharmacy +12
74
62
Labs & monitoringRoyal Medical Center +35
51
86
FulfillmentNovoCare Pharmacy +28
76
48
Contract termsEven
55
55
NovoCare Pharmacy · left barRoyal Medical Center · right bar

The numbers

MetricNovoCare PharmacyRoyal Medical Center
WeighScore55.2/10049.4/100
GradeCC
Scorecard rank#442#492
Semaglutide$349/mo (2.4 mg dose, brand-name)Not disclosed
TirzepatideNot disclosed$450/mo (2.5 mg dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
NovoCare Pharmacy

Graded #442 · C

Strengths

  • First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
  • $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
  • $349/mo standard self-pay is well below the ~$1,300/mo retail list price
  • Ships to all 50 states with no telehealth-platform middleman fees
  • Cold-chain logistics handled directly by Novo Nordisk

Where it loses points

  • Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
  • Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
  • No clinical support included — your own prescriber handles titration and side effects
  • Manufacturer-set pricing can change at any time
  • $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)
Royal Medical Center

Graded #492 · C

Strengths

  • Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
  • Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
  • All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
  • Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
  • Florida physician with 30+ years of practice — a strong physician-led care signal

Where it loses points

  • Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
  • Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
  • No LegitScript badge displayed
  • States served not enumerated — site says 'nationwide' with no state list
  • Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard